Table 4.

Logistic regression analysis: factors associated with the propensity of GPs to screen asymptomatic men for prostate cancer

Factors	Propensity to screen N (%)	Unadjusted OR (95% CI)	p Value	Adjusted OR (95% CI)	p Value
GP characteristics
Age group
<40	16/47 (34.0)	1		1
40–60	59/115 (51.3)	2.04 (1.01 to 4.13)	0.02**	1.09 (0.33 to 3.62)	0.88
>60	22/34 (64.7)	3.55 (1.41 to 8.97)		1.82 (0.32 to 10.42)	0.50
Gender
Male	64/128 (50.0)	1.06 (0.59 to 1.91)	0.85
Female	33/68 (48.5)	1
Length of practice (years)
≤10	25/70 (35.7)	1	0.03**	1	0.11
11–20	43/79 (54.4)	2.15 (1.11 to 4.16)		2.44 (0.82 to 7.23)	0.41
21–30	19/30 (63.3)	3.11 (1.28 to 7.56)		1.81 (0.44 to 7.47)	0.68
>30	10/17 (58.8)	2.57 (0.87 to 7.59)		1.49 (0.23 to 9.54
Knowledge
PPV of PSA
<30% (correct)	29/54 (53.7)	1	0.55
Overestimate	61/124 (49.2)	0.55 (0.19 to 1.63)
Not sure	7/18 (38.9)	0.66 (0.24 to 1.81)
PPV of DRE
<30% (correct)	24/50 (48.0)	1	0.61
Overestimate	58/111 (52.2)	0.81 (0.34 to 1.94)
Not sure	15/35 (42.8)	0.69 (0.32 to 1.47)
PPV of PSA and DRE
<50% (correct)	25/47 (53.2)	1	0.74
Overestimate	62/126 (49.2)	0.68 (0.25 to 1.85)
Not sure	10/23 (43.4)	0.79 (0.32 to 1.94)
Consider having a PSA test yourself*
No	2/13 (15.4)	1	0.01**	1	0.017**
Yes	65/115 (56.5)	7.3 (1.55 to 34.43)		6.88 (1.40 to 33.73)

*Among male participants.

**p<0.05.

GPs, general practitioners; DRE, digital rectal examination; PSA, prostrate-specific antigen; PPV, positive predictive value.